In vitro growth inhibition of bloodstream forms of Trypanosoma brucei and Trypanosoma congolense by iron chelators

Kinetoplastid Biology and Disease

Volumn 5, Issue , 2006, Pages

  Merschjohann, Karin ^a   Steverding, Dietmar ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,10 PHENANTHROLINE; 2,2' BIPYRIDINE; 2,3 DIHYDROXYBENZOIC ACID; 5 METHYLTROPOLONE; 8 QUINOLINOL; ALKALOID DERIVATIVE; ANTIPROTOZOAL AGENT; BATHOCUPROINE; BATHOPHENANTHROLINE; DEFEROXAMINE MESYLATE; DIMETHYLGLYOXIME; DIMINAZENE ACETURATE; ETHYLENEDIAMINE N,N' BIS(2 HYDROXYPHENYLACETIC ACID); IRON CHELATING AGENT; QUERCETIN; SULFOSALICYLIC ACID; SURAMIN; TRIPYRIDYLTRIAZINE; TROPOLONE; UNCLASSIFIED DRUG;

AFRICAN TRYPANOSOMIASIS; ANIMAL PARASITOSIS; ARTICLE; CELL STRAIN HL 60; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SELECTIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IRON METABOLISM; MORBIDITY; MORTALITY; NONHUMAN; STATISTICAL SIGNIFICANCE; TRYPANOSOMA BRUCEI; TRYPANOSOMA CONGOLENSE;

EID: 33748627441     PISSN: 14759292     EISSN: 14759292     Source Type: Journal    
DOI: 10.1186/1475-9292-5-3     Document Type: Article

References (27)

1. World Health Organization: African trypanosomiasis or sleeping sickness. World Health Organ Fact Sheet 2001, 259: [http://www.who.int/mediacentre/ factsheets/fs259/en/.]
2. World Health Organization: The world health report 2004: changing history. Geneva 2004.
3. Kristjanson PM, Swallow BM, Rowlands GJ, Kruska RL, de Leeuw PN: Measuring the costs of African animal trypanosomiasis, the potential benefits of control and returns to research. Agr Sys 1999, 59:79-98.
4. Croft SL: The current status of antiparasitic chemotherapy. Parasitology 1997, 114(Suppl):S3-S15.
5. Fairlamb AH: Chemotherapy of human African trypanosomiasis: current status and future prospects. Trends Parasitol 2003, 19:488-494.
6. Ross CA, Sutherland DV: Drug resistance in trypamosomatids. In Trypanosomiasis and Leishmaniasis. Biology and Control Edited by: Hide G, Mottram JC, Coombs GH, Holmes PH. Wallingford, Oxon: CAB International; 1997:259-269.
7. Matovu E, Seebeck T, Enyaru JCK, Kaminsky R: Drug resistance in Trypanosoma brucei spp., the causative agents of sleeping sickness in man and nagana in cattle. Microbes Infect 2001, 3:763-770.
8. Steverding D: Bloodstream forms of Trypanosoma brucei require only small amounts of iron for growth. Parasitol Res 1998, 84:59-62.
9. Breidbach T, Scory S, Krauth-Siegel RL, Steverding D: Growth inhibition of bloodstream forms of Trypanosoma brucei by the iron chelator deferoxamine. Int J Parasitol 2002, 32:473-479.
10. Räz B, Iten M, Grether-Bühler Y, Kaminisky R, Brun R: The Alamar Blue® assay to determine drug sensitivity of African trypanosomes (T. b. rhodesiense and T. b. gambiense) in vitro. Acta Trop 1997, 68:139-147.
11. Merschjohann K, Sporer F, Steverding D, Wink M: In vitro effect of alkaloids on bloodstream forms of Trypanosoma brucei and T. congolense. Planta Med 2001, 67:623-627.
12. Winkelmann G: Microbial siderophore-mediated transport. Biochem Soc Trans 2002, 30:691-696.
13. Peterson CM, Graziano JH, Grady RW, Jones RL, Vlassara HV, Canale VC, Miller DR, Cerami A: Chelation studies With 2,3-dihydroxybenzoic acid in patients with β-thalassaemia major. Br J Haematol 1976, 33:477-485.
14. Salamah AA: Effect of ethylenediamine di-o-hydroxyphenylacetic acid and transferrin on the growth of some bacterial strains in vitro. Microbiologica 1992, 15:361-366.
15. Deterding A, Dungey FA, Thompson K-T, Steverding D: Antitrypanosomal activities of DNA topoisomerase inhibitors. Acta Trop 2005, 93:311-316.
16. White GP, Jacobs A, Grady RW, Cerami A: The effect ofchelating agents on iron mobilization in Chang cell cultures. Blood 1976, 48:923-929.
17. Burgess J, Drasdo DN, Patel MS: Solubilities and solvation of aluminum (III), iron(III), and indium(III) 8-hydroxyquinolinates in methanol/ water mixtures. J Pharm Sci 1994, 83:54-7.
18. Boadi WY, Iyere PA, Adunyah SE: Effect of quercetin and genistein on copper- and iron-induced lipid peroxidation in methyl linolenate. J Appl Toxicol 2003, 23:363-369.
19. Romeo AM, Christen L, Niles EG, Kosman DJ: Intracellular chelation of iron by bipyridyl inhibits DNA virus replication: ribonucleotide reductase maturation as a probe of intracellular iron pools. J Biol Chem 2001, 276:24301-24308.
20. Mudasir, Wijaya K, Yoshioka N, Inoue H: DNA binding of iron(II) complexes with 1,10-phenanthroline and 4,7-diphenyl-1,10-phenanthroline: salt effect, ligand substituent effect, base pair specificity and binding strength. J Inorg Biochem 2003, 94:263-271.
21. Buss JL, Greene BT, Turner J, Torti FM, Torti SV: Iron chelators in cancer chemotherapy. Curr Top Med Chem 2004, 4:1623-1635.
22. Richardson DR: Molecular mechanisms of iron uptake by cells and the use of iron chelators for the treatment of cancer. Curr Med Chem 2005, 12:2711-2729.
23. Pahl PM, Horwitz LD: Cell permeable iron chelators as potential cancer chemotherapeutic agents. Cancer Invest 2005, 23:683-691.
24. Hirumi H, Hirumi K, Doyle JJ, Cross GAM: In vitro cloning of animal-infective bloodstream forms of Trypanosoma brucei. Parasitology 1980, 80:371-382.
25. Kaminsky R, Schmid C, Grether Y, Holk A, De Clercq E, Naesens L, Brun R: (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine [(S)-HPMPA]: a purine analogue with trypanocidal activity in vitro and in vivo. Trop Med Int Health 1996, 1:255-263.
26. Baltz T, Baltz D, Giroud C, Crockett J: Cultivation in a semi-defined medium of animal infective forms of Trypanosoma brucei, T. equiperdum, T. evansi, T. rhodesiense and T. gambiense. EMBO J 1985, 4:1273-1277.
27. 50 in studies of drug resistance of malaria parasites. Acta Trop 1993, 55:257-261.